Drug reference

Fidaxomicin

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 625

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Drug Action

Fidaxomicin is a macrocyclic antibacterial that is poorly absorbed from the gastro-intestinal tract, and, therefore, it should not be used to treat systemic infections.

PDF page 625

Indications And Dose

Clostridioides difficile infection ▶BY MOUTH ▶Adult: 200 mg every 12 hours for 10 days, limited clinical data is available on the use of ﬁdaxomicin in severe or life-threatening Clostridioides difﬁcile infection

PDF page 625

Cautions

Severe or life-threatening C. difﬁcile infection

PDF page 625

Allergy And Cross Sensitivity

Use with caution in macrolide hypersensitivity.

PDF page 625

National Funding Access Decisions

Scottish Medicines Consortium (SMC) decisions SMC No. 791/12 The Scottish Medicines Consortium has advised (July 2012) that ﬁdaxomicin (Diﬁclir ®) is accepted for restricted use within NHS Scotland to treat the ﬁrst recurrence of C. difﬁcile infection, on the advice of a microbiologist or specialist in infectious diseases.

PDF page 625

Safety

Interactions

→Appendix 1: ﬁdaxomicin

PDF page 625

Side Effects

▶Common or very common Constipation. nausea. vomiting ▶Uncommon Abdominal distension. appetite decreased. dizziness. dry mouth. ﬂatulence. headache. skin reactions. taste altered ▶Frequency not known Angioedema. dyspnoea. hypersensitivity

PDF page 625

Pregnancy

Manufacturer advises avoid—no information available.

PDF page 625

Breast Feeding

Manufacturer advises avoid—no information available.

PDF page 625

Hepatic Impairment

Manufacturer advises caution in moderate to severe impairment—limited information available.

PDF page 625

Renal Impairment

Manufacturer advises caution in severe impairment—no information available.

PDF page 625

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 9 ▶Dificlir (Astellas Pharma Ltd) Fidaxomicin 200 mg Dificlir 200mg tablets | 20 tablet P £1,350.00 DT = £1,350.00 Infection

PDF page 625

Dose text by age group

Adult

200 mg every 12 hours for 10 days, limited

First-line fragment. Read the complete Indications and Dose section above.

PDF page 625

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Fidaxomicin

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 625

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Drug Action

Fidaxomicin is a macrocyclic antibacterial that is poorly absorbed from the gastro-intestinal tract, and, therefore, it should not be used to treat systemic infections.

PDF page 625

Indications And Dose

PDF page 625

Cautions

Severe or life-threatening C. difﬁcile infection

PDF page 625

Allergy And Cross Sensitivity

Use with caution in macrolide hypersensitivity.

PDF page 625

National Funding Access Decisions

PDF page 625

Safety

Interactions

→Appendix 1: ﬁdaxomicin

PDF page 625

Side Effects

PDF page 625

Pregnancy

Manufacturer advises avoid—no information available.

PDF page 625

Breast Feeding

Manufacturer advises avoid—no information available.

PDF page 625

Hepatic Impairment

Manufacturer advises caution in moderate to severe impairment—limited information available.

PDF page 625

Renal Impairment

Manufacturer advises caution in severe impairment—no information available.

PDF page 625

Dose and formulations

Medicinal Forms

PDF page 625

Dose text by age group

Adult

200 mg every 12 hours for 10 days, limited

First-line fragment. Read the complete Indications and Dose section above.

PDF page 625

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.